

# NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

## Single Technology Appraisal

### Netarsudil-latanoprost for previously treated open-angle glaucoma or ocular hypertension ID1363

#### Provisional Stakeholder List

Consultees	Commentators (no right to submit or appeal)
<p><u>Company</u></p> <ul style="list-style-type: none"> <li>• Aerie Pharmaceuticals (netarsudil-latanoprost)</li> </ul> <p><u>Patient/carer groups</u></p> <ul style="list-style-type: none"> <li>• Eyecare Trust</li> <li>• Fight for Sight</li> <li>• Glaucoma UK</li> <li>• Henshaws Society for Blind People</li> <li>• International Glaucoma Association</li> <li>• Macular Society</li> <li>• National Federation of the Blind of the UK</li> <li>• Organisation of Blind Africans &amp; Caribbeans</li> <li>• Royal National Institute of Blind People</li> <li>• SeeAbility</li> <li>• Sense</li> <li>• South Asian Health Foundation</li> <li>• Specialised Healthcare Alliance</li> <li>• Thomas Pocklington Trust</li> </ul> <p><u>Professional groups</u></p> <ul style="list-style-type: none"> <li>• Association for Independent Optometrists and Dispensing Opticians</li> <li>• Association of Health Professionals in Ophthalmology</li> <li>• Association of Optometrists</li> <li>• British and Irish Orthoptic Society</li> <li>• British Geriatrics Society</li> <li>• British Ophthalmic Anaesthesia Society</li> <li>• College of Optometrists</li> <li>• Optical Confederation</li> <li>• Oxford Eye Foundation</li> <li>• Royal College of General Practitioners</li> <li>• Royal College of Nursing</li> <li>• Royal College of Ophthalmologists</li> <li>• Royal College of Pathologists</li> <li>• Royal College of Physicians</li> <li>• Royal Pharmaceutical Society</li> <li>• Royal Society of Medicine</li> <li>• UK Clinical Pharmacy Association</li> </ul>	<p><u>General</u></p> <ul style="list-style-type: none"> <li>• All Wales Therapeutics and Toxicology Centre</li> <li>• Allied Health Professionals Federation</li> <li>• Board of Community Health Councils in Wales</li> <li>• British National Formulary</li> <li>• Care Quality Commission</li> <li>• Department of Health, Social Services and Public Safety for Northern Ireland</li> <li>• Healthcare Improvement Scotland</li> <li>• Medicines and Healthcare products Regulatory Agency</li> <li>• National Association of Primary Care</li> <li>• National Pharmacy Association</li> <li>• NHS Alliance</li> <li>• NHS Confederation</li> <li>• Scottish Medicines Consortium</li> <li>• Wales Council for the Blind</li> <li>• Welsh Health Specialised Services Committee</li> </ul> <p><u>Possible comparator companies</u></p> <ul style="list-style-type: none"> <li>• Accord (bimatoprost, brinzolamide, dorzolamide, latanoprost, timolol maleate, travoprost)</li> <li>• Advanz Pharma (acetazolamide)</li> <li>• Allergan (bimatoprost, levobunolol hydrochloride, timolol maleate, brimonidine tartrate)</li> <li>• Aspire Pharma (bimatoprost, brinzolamide, dorzolamide, timolol maleate, travoprost)</li> <li>• Bausch &amp; Lomb UK (pilocarpine hydrochloride/nitrate, timolol maleate)</li> <li>• Brown &amp; Burk UK (dorzolamide, timolol maleate)</li> <li>• FDC International (betaxolol, brimonidine tartrate, dorzolamide, latanoprost, timolol maleate)</li> <li>• Galderma (brimonidine tartrate)</li> <li>• Glenmark Pharmaceuticals (dorzolamide)</li> <li>• Kent Pharmaceuticals (dorzolamide,</li> </ul>

Provisional stakeholder list for the single technology appraisal of netarsudil-latanoprost for previously treated open-angle glaucoma or ocular hypertension [ID1363]  
Issue date: November 2021.

Consultees	Commentators (no right to submit or appeal)
<p><u>Others</u></p> <ul style="list-style-type: none"> <li>• Department of Health and Social Care</li> <li>• NHS England</li> <li>• NHS Hull CCG</li> <li>• NHS North Kirklees CCG</li> <li>• Welsh Government</li> </ul>	<p>latanoprost, timolol maleate)</p> <ul style="list-style-type: none"> <li>• Martindale Pharma (dorzolamide, latanoprost, pilocarpine hydrochloride/nitrate)</li> <li>• Medicom Healthcare (latanoprost)</li> <li>• Merus Labs Luxco II S.à R.L (pilocarpine hydrochloride/nitrate)</li> <li>• Mylan (bimatoprost, brinzolamide, timolol maleate, latanoprost, travoprost)</li> <li>• Novartis (apraclonidine, betaxolol, brimonidine tartrate, brinzolamide, timolol maleate, travoprost)</li> <li>• Pfizer (latanoprost,)</li> <li>• Sandoz (bimatoprost, brinzolamide, travoprost)</li> <li>• Santen UK (dorzolamide, tafluprost, timolol maleate)</li> <li>• Thea Pharmaceuticals (latanoprost, timolol maleate)</li> <li>• Thornton &amp; Ross (brinzolamide)</li> <li>• Viartis (travoprost)</li> <li>• Zentiva (brinzolamide, dorzolamide, latanoprost, timolol maleate)</li> </ul> <p><u>Relevant research groups</u></p> <ul style="list-style-type: none"> <li>• Cochrane Eyes and Vision Group</li> <li>• Cochrane UK</li> <li>• Eye Hope</li> <li>• Genomics England</li> <li>• Institute of Ophthalmology, University College London</li> <li>• MRC Clinical Trials Unit</li> <li>• National Eye Research Centre Charity</li> <li>• National Institute for Health Research</li> </ul> <p><u>Associated Public Health Groups</u></p> <ul style="list-style-type: none"> <li>• Public Health Wales</li> <li>• UK Health Security Agency</li> </ul>

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the stakeholder list, and which organisations we should include that have a particular focus on relevant equality issues.

**Definitions:**

Consultees

Organisations that accept an invitation to participate in the appraisal; the company that markets the technology; national professional organisations; national patient organisations;

Provisional stakeholder list for the single technology appraisal of netarsudil-latanoprost for previously treated open-angle glaucoma or ocular hypertension [ID1363]  
Issue date: November 2021.

the Department of Health and Social Care and the Welsh Government and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical specialists and has the right to appeal against the Final Appraisal Document (FAD).

All non-company consultees are invited to submit a statement<sup>1</sup>, respond to consultations, nominate clinical specialists or patient experts and have the right to appeal against the Final Appraisal Document (FAD).

### Commentators

Organisations that engage in the appraisal process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FAD for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; other related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Alliance, and the British National Formulary).

All non-company commentators are invited to nominate clinical specialists or patient experts.

---

<sup>1</sup> Non-company consultees are invited to submit statements relevant to the group they are representing.